147 related articles for article (PubMed ID: 30249692)
1.
Sampaio ADG; Gontijo AVL; Araujo HM; Koga-Ito CY
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249692
[TBL] [Abstract][Full Text] [Related]
2. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species.
Chamilos G; Lionakis MS; Lewis RE; Lopez-Ribot JL; Saville SP; Albert ND; Halder G; Kontoyiannis DP
J Infect Dis; 2006 Apr; 193(7):1014-22. PubMed ID: 16518764
[TBL] [Abstract][Full Text] [Related]
3. Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris.
Wurster S; Bandi A; Beyda ND; Albert ND; Raman NM; Raad II; Kontoyiannis DP
J Antimicrob Chemother; 2019 Jul; 74(7):1904-1910. PubMed ID: 31225606
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacokinetics/pharmacodynamics modeling and efficacy against systemic candidiasis in Drosophila melanogaster of a bisaryloxypropanamine derivative.
Dalla Lana DF; Kaminski TFA; Lavorato SN; Merkel S; Zanette RA; da Rosa PD; Staudt KJ; de Araújo BV; da Costa B; Quatrin PM; Bazana LCG; Ferreira FA; Caurio CFB; de Andrade SF; Alves RJ; Fuentefria AM
Med Mycol; 2021 Jan; 59(1):58-66. PubMed ID: 32407486
[TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutical and antifungal properties of ellagic acid-cyclodextrin using an
Gontijo AV; G Sampaio AD; Koga-Ito CY; Salvador MJ
Future Microbiol; 2019 Jul; 14():957-967. PubMed ID: 31373226
[No Abstract] [Full Text] [Related]
6. Immune-deficient Drosophila melanogaster: a model for the innate immune response to human fungal pathogens.
Alarco AM; Marcil A; Chen J; Suter B; Thomas D; Whiteway M
J Immunol; 2004 May; 172(9):5622-8. PubMed ID: 15100306
[TBL] [Abstract][Full Text] [Related]
7. The Drosophila Toll pathway controls but does not clear Candida glabrata infections.
Quintin J; Asmar J; Matskevich AA; Lafarge MC; Ferrandon D
J Immunol; 2013 Mar; 190(6):2818-27. PubMed ID: 23401590
[TBL] [Abstract][Full Text] [Related]
8. Ellagic Acid-Cyclodextrin Complexes for the Treatment of Oral Candidiasis.
Sampaio ADG; Gontijo AVL; Lima GMG; de Oliveira MAC; Lepesqueur LSS; Koga-Ito CY
Molecules; 2021 Jan; 26(2):. PubMed ID: 33477918
[TBL] [Abstract][Full Text] [Related]
9. Antifungal activity and toxicological parameters of 8-hydroxyquinoline-5-sulfonamides using alternative animal models.
Pippi B; Joaquim AR; Merkel S; Zanette RA; Nunes MEM; da Costa Silva DG; Schimith LE; Teixeira ML; Franco JL; Fernandes de Andrade S; Fuentefria AM
J Appl Microbiol; 2021 Jun; 130(6):1925-1934. PubMed ID: 33128257
[TBL] [Abstract][Full Text] [Related]
10. Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris.
Wurster S; Albert ND; Kontoyiannis DP
Methods Mol Biol; 2022; 2517():299-316. PubMed ID: 35674964
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and -resistant isolates of Candida albicans.
de Sá NP; de Paula LFJ; Lopes LFF; Cruz LIB; Matos TTS; Lino CI; de Oliveira RB; de Souza-Fagundes EM; Fuchs BB; Mylonakis E; Johann S
J Glob Antimicrob Resist; 2018 Sep; 14():287-293. PubMed ID: 29715565
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an extract of North American ginseng (Panax quinquefolius L.) in Candida albicans-infected complement-deficient mice.
Trammell RA; Cox L; Pikora J; Murphy LL; Toth LA
J Ethnopharmacol; 2012 Jan; 139(2):414-21. PubMed ID: 22138349
[TBL] [Abstract][Full Text] [Related]
13. Antifungal Activity of Ellagic Acid In Vitro and In Vivo.
Li ZJ; Guo X; Dawuti G; Aibai S
Phytother Res; 2015 Jul; 29(7):1019-25. PubMed ID: 25919446
[TBL] [Abstract][Full Text] [Related]
14. Plant extracts: initial screening, identification of bioactive compounds and effect against Candida albicans biofilms.
Brighenti FL; Salvador MJ; Gontijo AVL; Delbem ACB; Delbem ÁCB; Soares CP; de Oliveira MAC; Girondi CM; Koga-Ito CY
Future Microbiol; 2017 Jan; 12():15-27. PubMed ID: 27922746
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and antifungal activity of a novel formulated nanocomposite containing Indolicidin and Graphene oxide against disseminated candidiasis.
Farzanegan A; Roudbary M; Falahati M; Khoobi M; Gholibegloo E; Farahyar S; Karimi P; Khanmohammadi M
J Mycol Med; 2018 Dec; 28(4):628-636. PubMed ID: 30126717
[TBL] [Abstract][Full Text] [Related]
16. Ellagic acid prolongs the lifespan of Drosophila melanogaster.
Kharat P; Sarkar P; Mouliganesh S; Tiwary V; Priya VBR; Sree NY; Annapoorna HV; Saikia DK; Mahanta K; Thirumurugan K
Geroscience; 2020 Feb; 42(1):271-285. PubMed ID: 31786733
[TBL] [Abstract][Full Text] [Related]
17. Targeting Candida albicans filamentation for antifungal drug development.
Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of disseminated murine Candida albicans infection reveals unexpected host sites of fungal persistence during antifungal therapy.
Jacobsen ID; Lüttich A; Kurzai O; Hube B; Brock M
J Antimicrob Chemother; 2014 Oct; 69(10):2785-96. PubMed ID: 24951534
[TBL] [Abstract][Full Text] [Related]
19. Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models.
Chamilos G; Nobile CJ; Bruno VM; Lewis RE; Mitchell AP; Kontoyiannis DP
J Infect Dis; 2009 Jul; 200(1):152-7. PubMed ID: 19463063
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis.
Tavares PM; Thevissen K; Cammue BP; François IE; Barreto-Bergter E; Taborda CP; Marques AF; Rodrigues ML; Nimrichter L
Antimicrob Agents Chemother; 2008 Dec; 52(12):4522-5. PubMed ID: 18824606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
